Seelos Therapeutics Gross Profit 2010-2022 | SEEL

Seelos Therapeutics gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Seelos Therapeutics Annual Gross Profit
(Millions of US $)
2021 $
2020 $
2019 $0
2018 $
2017 $
2016 $
2015 $4
2014 $8
2013 $-0
2012 $4
2011 $2
2010 $1
2009 $3
Seelos Therapeutics Quarterly Gross Profit
(Millions of US $)
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $0
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $3
2015-09-30 $1
2015-06-30 $-0
2015-03-31 $0
2014-12-31 $2
2014-09-30 $1
2014-06-30 $5
2014-03-31
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $-1
2012-12-31 $-0
2012-09-30 $3
2012-06-30 $0
2012-03-31 $1
2011-12-31 $0
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $-1
2010-09-30 $1
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.072B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00